Reverse DCF
What growth does the market imply for CONCORDBIO?
Working backwards from the current price to find the FCF growth assumption baked in.
aggressive
14.3% implied annual FCF growth
The market is pricing in above-average growth. Achievable for a high-quality business but leaves limited margin for error — any slowdown could hurt the price.
Current Price
₹1,048
Historical Growth
4.9%
FCF Yield
2.65%
Price / FCF
37.7x
Plain English
To justify today's price of $1047.50, CONCORDBIO.NS needs to grow its free cash flow at 14.3% per year for the next 10 years. That is 9.4% faster than its historical growth rate of 4.9%. This is optimistic but not impossible for a high-quality business. The stock leaves little room for error — any slowdown could hurt the price.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Historical | 4.9% | ₹499 | -52.4% |
| Half implied | 7.1% | ₹595 | -43.2% |
| GDP rate | 10.0% | ₹744 | -28.9% |
| Implied | 14.3% | ₹1,044 | -0.4% |
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, Monte Carlo, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.